JP2018524298A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524298A5 JP2018524298A5 JP2017564058A JP2017564058A JP2018524298A5 JP 2018524298 A5 JP2018524298 A5 JP 2018524298A5 JP 2017564058 A JP2017564058 A JP 2017564058A JP 2017564058 A JP2017564058 A JP 2017564058A JP 2018524298 A5 JP2018524298 A5 JP 2018524298A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- ezh2 inhibitor
- ezh2
- inhibitor according
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OCGCJISPOYIXKL-MGCOHNPYSA-N CCN[C@H](CC1)CC[C@@H]1N(C)C Chemical compound CCN[C@H](CC1)CC[C@@H]1N(C)C OCGCJISPOYIXKL-MGCOHNPYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173685P | 2015-06-10 | 2015-06-10 | |
| US62/173,685 | 2015-06-10 | ||
| PCT/US2016/037024 WO2016201328A1 (en) | 2015-06-10 | 2016-06-10 | Ezh2 inhibitors for treating lymphoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524298A JP2018524298A (ja) | 2018-08-30 |
| JP2018524298A5 true JP2018524298A5 (https=) | 2019-07-11 |
| JP6890097B2 JP6890097B2 (ja) | 2021-06-18 |
Family
ID=57504554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564058A Expired - Fee Related JP6890097B2 (ja) | 2015-06-10 | 2016-06-10 | リンパ腫を処置するためのｅｚｈ２阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20180311251A1 (https=) |
| EP (1) | EP3307713A4 (https=) |
| JP (1) | JP6890097B2 (https=) |
| CN (1) | CN107635965A (https=) |
| AU (2) | AU2016275051A1 (https=) |
| CA (1) | CA2988816A1 (https=) |
| EA (1) | EA201890009A1 (https=) |
| IL (1) | IL256056A (https=) |
| MX (2) | MX387885B (https=) |
| WO (1) | WO2016201328A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| KR20230156450A (ko) | 2012-10-15 | 2023-11-14 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| CN116019921A (zh) | 2013-12-06 | 2023-04-28 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| BR112016029492A2 (pt) | 2014-06-17 | 2017-10-17 | Eisai R&D Man Co Ltd | método para tratamento de linfoma não hodgkin |
| HUE062159T2 (hu) * | 2014-11-17 | 2023-10-28 | Epizyme Inc | Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal |
| AU2016275051A1 (en) | 2015-06-10 | 2017-12-07 | Epizyme, Inc. | EZH2 inhibitors for treating lymphoma |
| WO2017035234A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
| EP3407978A4 (en) | 2016-01-29 | 2020-01-15 | Epizyme Inc | POLYTHERAPY FOR THE TREATMENT OF CANCER |
| CA3025933A1 (en) | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| WO2017218953A1 (en) * | 2016-06-17 | 2017-12-21 | Epizyme, Inc. | Ezh2 inhibitors for treating cancer |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| AU2018275123A1 (en) | 2017-06-02 | 2020-01-30 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| CN111093660A (zh) | 2017-09-05 | 2020-05-01 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| US20210000815A1 (en) * | 2017-12-28 | 2021-01-07 | Constellation Pharmaceuticals, Inc. | Pharmacokinetic enhancement of ezh2 inhibitors through combination therapies |
| US11220515B2 (en) | 2018-01-26 | 2022-01-11 | Yale University | Imide-based modulators of proteolysis and associated methods of use |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| MX2021001957A (es) | 2018-08-22 | 2021-07-15 | Cullgen Shanghai Inc | Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk). |
| TWI837231B (zh) * | 2018-11-29 | 2024-04-01 | 日商第一三共股份有限公司 | 含有ｅｚｈ１／２雙重抑制劑之醫藥組合及其用途 |
| WO2020165402A1 (en) * | 2019-02-14 | 2020-08-20 | Westfälische Wilhelms-Universität Münster | Gd2-upregulation by ezh2 inhibition in cancer therapy |
| JP2022545467A (ja) | 2019-08-22 | 2022-10-27 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法 |
| CN110950834A (zh) * | 2019-11-26 | 2020-04-03 | 济南大学 | 新型eed-ezh2相互作用小分子抑制剂的确定和评价 |
| CN110960525A (zh) * | 2019-11-26 | 2020-04-07 | 济南大学 | 新型eed-ezh2相互作用抑制剂的确定和评价 |
| CA3173262A1 (en) | 2020-02-26 | 2021-09-02 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
| CN111303133A (zh) * | 2020-03-25 | 2020-06-19 | 清华大学 | 降解ezh2蛋白的小分子化合物 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| CN120884593A (zh) * | 2025-09-12 | 2025-11-04 | 北京大学第三医院（北京大学第三临床医学院） | 他泽司他在制备预防和/或治疗类风湿性关节炎的药物中的用途 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA110112C2 (uk) * | 2010-05-07 | 2015-11-25 | Глаксосмітклайн Ллс | Індоли |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| BR112013005806B1 (pt) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| ES2951688T3 (es) | 2011-02-28 | 2023-10-24 | Epizyme Inc | Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TWI598336B (zh) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
| CA2850570A1 (en) * | 2011-09-30 | 2013-04-04 | Glaxosmithkline Llc | Methods of treating cancer |
| EP3536314A1 (en) | 2012-03-12 | 2019-09-11 | Epizyme, Inc. | Inhibitors of human ezh2, and methods of use thereof |
| SG10201912111TA (en) | 2012-04-13 | 2020-02-27 | Epizyme Inc | Combination therapy for treating cancer |
| PT3184523T (pt) | 2012-04-13 | 2019-09-26 | Eisai R&D Man Co Ltd | Bromidrato de n-((4,6-dimetil-2-oxo-l,2-di-hidropiridin- 3-il)metil)-5-(etil(tetra-hidro-2h-piran-4-il)amino)-4- metil-4¿-(morfolinometil)-[l,1¿-bofenil]-3-carboxamida para utilização no tratamento de uma doença proliferativa celular do sistema hematológico |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| MX2015004721A (es) * | 2012-10-15 | 2016-01-25 | Epizyme Inc | Compuestos de benceno sustituidos. |
| KR20230156450A (ko) | 2012-10-15 | 2023-11-14 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| EP2914296B2 (en) | 2012-11-01 | 2021-09-29 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| US20150283142A1 (en) * | 2013-03-15 | 2015-10-08 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| US20140120083A1 (en) | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| EP2934531A4 (en) | 2012-12-19 | 2016-06-15 | Glaxosmithkline Llc | COMBINATION |
| CA2894222A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| AU2013361060B2 (en) | 2012-12-21 | 2018-04-19 | Epizyme, Inc. | 1,4-pyridone compounds |
| CA2903572A1 (en) | 2013-03-15 | 2014-10-23 | Epizyme, Inc. | Substituted benzene compounds |
| US9776996B2 (en) | 2013-03-15 | 2017-10-03 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| SG11201509842SA (en) * | 2013-05-30 | 2015-12-30 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| WO2015010078A2 (en) | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US10150764B2 (en) | 2013-07-19 | 2018-12-11 | Epizyme, Inc. | Substituted benzene compounds |
| MA38949A1 (fr) | 2013-10-16 | 2017-07-31 | Eisai R&D Man Co Ltd | Forme saline d'hydrochlorure pour inhibition d'ezh2 |
| WO2015058125A1 (en) | 2013-10-18 | 2015-04-23 | Epizyme, Inc. | Method of treating cancer |
| CN116019921A (zh) | 2013-12-06 | 2023-04-28 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| BR112016029492A2 (pt) | 2014-06-17 | 2017-10-17 | Eisai R&D Man Co Ltd | método para tratamento de linfoma não hodgkin |
| WO2015200650A1 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds |
| EA201790845A1 (ru) | 2014-10-16 | 2017-08-31 | Эпизайм, Инк. | Способ лечения рака |
| EP3215160A4 (en) * | 2014-11-06 | 2018-08-08 | Dana-Farber Cancer Institute, Inc. | Use of compositions modulating chromatin structure for graft versus host disease (gvhd) |
| HUE062159T2 (hu) | 2014-11-17 | 2023-10-28 | Epizyme Inc | Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal |
| JP6544507B2 (ja) | 2015-02-09 | 2019-07-17 | 日本精機株式会社 | ヘッドアップディスプレイ装置 |
| WO2016172199A1 (en) | 2015-04-20 | 2016-10-27 | Epizyme, Inc. | Combination therapy for treating cancer |
| AU2016275051A1 (en) | 2015-06-10 | 2017-12-07 | Epizyme, Inc. | EZH2 inhibitors for treating lymphoma |
| KR20170095656A (ko) | 2016-02-15 | 2017-08-23 | 동부대우전자 주식회사 | 방열구조를 갖는 세탁기 |
-
2016
- 2016-06-10 AU AU2016275051A patent/AU2016275051A1/en not_active Abandoned
- 2016-06-10 EA EA201890009A patent/EA201890009A1/ru unknown
- 2016-06-10 CA CA2988816A patent/CA2988816A1/en active Pending
- 2016-06-10 MX MX2017015938A patent/MX387885B/es unknown
- 2016-06-10 WO PCT/US2016/037024 patent/WO2016201328A1/en not_active Ceased
- 2016-06-10 EP EP16808443.2A patent/EP3307713A4/en not_active Withdrawn
- 2016-06-10 JP JP2017564058A patent/JP6890097B2/ja not_active Expired - Fee Related
- 2016-06-10 CN CN201680032950.XA patent/CN107635965A/zh active Pending
- 2016-06-10 US US15/580,908 patent/US20180311251A1/en not_active Abandoned
-
2017
- 2017-12-03 IL IL256056A patent/IL256056A/en unknown
- 2017-12-07 MX MX2021013830A patent/MX2021013830A/es unknown
-
2019
- 2019-01-17 US US16/250,211 patent/US11202781B2/en not_active Expired - Fee Related
-
2021
- 2021-03-18 AU AU2021201705A patent/AU2021201705A1/en not_active Abandoned
- 2021-11-15 US US17/526,307 patent/US11951109B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018524298A5 (https=) | ||
| JP2019521988A5 (https=) | ||
| JP2019514854A5 (https=) | ||
| JP2011505347A5 (https=) | ||
| JP2017518334A5 (https=) | ||
| JP2009504763A5 (https=) | ||
| JP2018021051A5 (https=) | ||
| RU2018106453A (ru) | Соединения | |
| RU2006109467A (ru) | Способы лечения рака с использованием ингибиторов hdac | |
| JP2005506352A5 (https=) | ||
| RU2013124824A (ru) | Твердые дисперсии, содержащие средства, вызывающие апоптоз | |
| JP2016539134A5 (https=) | ||
| JP2008509187A5 (https=) | ||
| FI3157527T3 (fi) | Ezh2-inhibiittoreita lymfoman hoitoon | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2016512834A5 (https=) | ||
| JP2018524390A5 (https=) | ||
| RU2015107877A (ru) | Способы лечения болезни альцгеймера и фармацевтические композиции | |
| JP2016534063A5 (https=) | ||
| JP2006505581A5 (https=) | ||
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| RU2017112308A (ru) | Композиции и способы для лечения бессонницы | |
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| ES2698363T3 (es) | Composiciones de oxprenolol para tratar el cáncer | |
| JP2008534453A5 (https=) |